EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma

被引:0
作者
Maria Colombino
Panagiotis Paliogiannis
Antonio Cossu
Davide Adriano Santeufemia
Maria Cristina Sini
Milena Casula
Grazia Palomba
Antonella Manca
Marina Pisano
Valentina Doneddu
Giuseppe Palmieri
机构
[1] Institute Biomolecular Chemistry,Unit of Cancer Genetics
[2] CNR,Department of Medical, Surgical, and Experimental Sciences
[3] University of Sassari,undefined
[4] Medical Oncology Unit,undefined
[5] Civil Hospital,undefined
来源
BMC Pulmonary Medicine | / 19卷
关键词
Lung cancer; Adenocarcinoma; Targeted therapies;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 225 条
[1]  
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]  
Miller KD(2013)Lung cancer epidemiology in North Sardinia, Italy Multidiscip Respir Med 8 45-165
[3]  
Jemal A(2013)Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 143 142-70
[4]  
Paliogiannis P(2018)Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer Expert Rev Anticancer Ther 18 63-379
[5]  
Attene F(2018)Molecular targeted therapy for non-small cell lung cancer: the reality in China and coping strategy Prac J Med Pharm 35 373-191
[6]  
Cossu A(2015)Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma Mol Med Rep 12 187-2394
[7]  
Budroni M(2019)Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing Front Pharmacol 10 230-870
[8]  
Cesaraccio R(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-159
[9]  
Tanda F(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-8541
[10]  
Rivera MP(2018)Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology J Mol Diagn 20 129-460